Latest News

Press Release – Oslo, Norway, September 15, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces a clinical data presentation and highlights from the 2021 American Urological Association Annual Congress (AUA2021), which was held virtually September 10-13, 2021. During the program, new results from a study using Blue Light Cystoscopy (BLC^®) with Cysview^® in the surveillance setting were reported in a podium presentation, and separately, BLC with Cysview was discussed in an Expert Presentation on Surgical Techniques.

Press Release – Oslo, Norway September 8, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews and participate in meetings with investors at two upcoming conferences: the H.C. Wainwright 23^rd Annual Global Investment Conference to be held September 13-15, 2021, and the Danske Bank Securities Life Science Seminar on September 20, 2021.

Oslo, Norway, 1 September 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 31 August 2021 regarding exercise of share options and sale of own shares, together with primary insider notifications.

Oslo, Norway, 1 September 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 August 2021 regarding a share capital increase following the exercise of share options.

Press Release – Oslo, Norway, September 1, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.

Oslo, Norway, 31 August 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 August 2021 regarding exercise of share options.

Oslo, Norway, 30 August 2021: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 30 August 2021 exercised a total of 25,500 options distributed as follows:

Press release – Oslo, Norway, 25 August 2021: Photocure ASA (Photocure, PHO: OSE) announces that it has reached agreement with BioSyent Pharma Inc. (“BioSyent”) to reacquire the marketing and distribution rights to Cysview^® in Canada. The parties entered into a final agreement today, stipulating that commercial rights will transfer to Photocure on January 1^st, 2022. The reacquisition of marketing and distribution rights enables Photocure’s direct management of the Cysview brand in Canada and consolidates the territory into Photocure’s existing U.S. business to form its North America sales segment.

Oslo, Norway, 23 August 2021 - The board of directors in Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Press Release – Oslo, Norway August 23, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients,  announces that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present a corporate overview and participate in meetings with investors at the Nordea Annual Small & Mid Cap Days 2021 conference to be held virtually August 24-26, 2021.

Oslo, Norway, August 16, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that the Marketing Authorization for Hexvix^® in Chile has been granted. Photocure’s partner and exclusive distributor, Genotests SpA, received the official regulatory approval by the Instituto de Salud Pública de Chile on August 12th.

Oslo, Norway, 11 August 2021: Photocure ASA (OSE:PHO) today reported Hexvix^®/Cysview^® revenues of NOK 88.9 million in the second quarter of 2021 (Q2 2020: NOK 53.5), and EBITDA of NOK 5.8 million (NOK -8.9 million), driven by growth in the U.S. segment and the continued successful launch in European markets reacquired in 2020. Despite business challenges due to ongoing surges of Covid-19 and its variants in certain territories, Photocure plans to increase investment in commercial activities in the second half of 2021 to capitalize on improving access to care and to further penetrate the large potential market opportunity for Hexvix/Cysview in its direct global markets.

Oslo, Norway, 4 August 2021: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2021 financial results on Wednesday 11 August 2021 at 07:30 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

Oslo, Norway, 28 July 2021: Photocure ASA (OSE: PHO), held an extraordinary general meeting on 28 July 2021 at 17:00 hours (CEST).

Oslo, Norway, July 13, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces highlights from a successful European Association of Urology virtual congress, continuing the steady flow of new scientific data being presented on the importance of Blue Light Cystoscopy (BLC^®) in Bladder Cancer management.

Oslo, Norway, 7 July 2021: Photocure ASA (OSE: PHO), calls for an extraordinary general meeting of Photocure to be held in Advokatfirmaet Selmer AS' premises in Tjuvholmen allé 1, 0252 Oslo on 28 July 2021 at 17:00 hours (CEST).

Oslo, Norway, 7 July 2021: Photocure ASA (OSE: PHO), calls for an extraordinary general meeting of Photocure to be held in Advokatfirmaet Selmer AS' premises in Tjuvholmen allé 1, 0252 Oslo on 28 July 2021 at 17:00 hours (CEST).

Press Release – Oslo, Norway, 23 June, 2021: Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology. The study objective was to determine the estimated budget impact to practices that incorporate blue light cystoscopy (BLC^®) with hexaminolevulinate HCl (HAL) for the surveillance of non-muscle-invasive bladder cancer (NMIBC) in the clinic setting.

Oslo, Norway, 22 June, 2021: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals (Asieris) has administered the first European patient in its phase III clinical trial for APL-1702 (Cevira^®).